News

Prana presents unique drug platform at World Orphan Drug Congress

Prana regains compliance with NASDAQ continued listing requirements and continues to work towards FDA submission

Prana Biotechnology AGM Presentation

Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) will host a webcast of its Annual General Meeting on Friday, November 13, 2015, at 9.30am AEDT.

Prana Biotechnology Limited has released its Preliminary Final Report (Appendx 4E) for the 2014-15 financial year.

Prana Biotechnology yesterday announced its financial results for the 12 months to June 30, 2015.

Prana Biotechnology has today announced the safety outcomes of the IMAGINE Extension study in patients with Alzheimer’s disease. A 250mg dose of PBT2 was safe and well tolerated over a 2 year period. The independent Data Safety Monitoring Board did not identify any safety concerns related to PBT2.

Prana Biotechnology Limited has today announced that it has received a $6.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.

Prana Biotechnology Limited has today announced that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington’s disease, stating that Prana has shown that PBT2 might be of significant benefit for patients with Huntington’s disease.